EPS for Aptose Biosciences Inc. (APS) Expected At $-0.16

March 14, 2018 - By Ellis Scott

 EPS for Aptose Biosciences Inc. (APS) Expected At $ 0.16

Analysts expect Aptose Biosciences Inc. (TSE:APS) to report $-0.16 EPS on March, 27 after the close.They anticipate $0.10 EPS change or 38.46 % from last quarter’s $-0.26 EPS. After having $-0.14 EPS previously, Aptose Biosciences Inc.’s analysts see 14.29 % EPS growth. The stock increased 3.85% or $0.18 during the last trading session, reaching $4.85. About 67,437 shares traded or 7.08% up from the average. Aptose Biosciences Inc. (TSE:APS) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $127.90 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Another recent and important Aptose Biosciences Inc. (TSE:APS) news was published by Globenewswire.com which published an article titled: “Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase …” on March 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.